Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Aug 09, 2022 3:23pm
167 Views
Post# 34882623

RE:RE:Anyone buying at the current SP?

RE:RE:Anyone buying at the current SP? Based on the low volume of shares traded and the downward arc of the shre price today, it shoiudl be pretty evident there is absolutely no anticipation of anything meaningful happening at the Cannacorrd presentation tomorrow. The stock has already bled out. No one is paying attention or anticipating anything about it other than us as is evident from the low volume of shares traded and a stock that is not trading like it is connected to any current theme in the market (such as the recent huge run in small biotechs).

The Canaccord presention is unlikely to break new ground. But at least they are trying to get the stock back on investor's radar now.

Trogarzon wrote: The answer is no... lots of anticipation of the 42nb Cannaccord show tomorrow... another reheated preclinical nice picture presentation probably.. prepare to be amazed.. woo boo.. peters out... poof...


<< Previous
Bullboard Posts
Next >>